Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
Phase 1
Withdrawn
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- F2G Biotech GmbH
- Registration Number
- NCT03036046
Radiolabelled IV and Oral Metabolism Study of F901318
Phase 1
Withdrawn
- Conditions
- Invasive Aspergillosis
- Interventions
- Drug: IV F901318Drug: Oral F901318
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- F2G Biotech GmbH
- Registration Number
- NCT02912026
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, Nottinghamshire, United Kingdom
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
Phase 1
Withdrawn
- Conditions
- Pulmonary Aspergillosis - InvasiveAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- F2G Biotech GmbH
- Registration Number
- NCT02856178
Evaluation of Immediate Release Tablet
Phase 1
Completed
- Conditions
- Invasive Aspergillosis
- Interventions
- Drug: F901318 IR FedDrug: F901318 SDDDrug: F901318 IRDrug: F901318 IR Fasting
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT02808741
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects
Phase 1
Completed
- Conditions
- Invasive Aspergillosis
- Interventions
- Drug: Placebo Dose level C oralDrug: F901318 Dose level C oralDrug: F901318 Dose level A oralDrug: Placebo dose level A oralDrug: F901318 Dose level B oralDrug: Placebo dose level B oral
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT02737371
- Locations
- 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, Glamorgan, United Kingdom
Study of Potential for Interaction of Fluconazole With F901318
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT02730442
- Locations
- 🇬🇧
CELERION, Belfast, Northern Ireland, United Kingdom
Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 20
- Registration Number
- NCT02680808
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Single Ascending Oral Dose Study of F901318
Phase 1
Completed
- Conditions
- Invasive Aspergillosis
- Interventions
- Other: Placebo safetyDrug: F901318 safetyOther: Placebo tolerabilityDrug: F901318 tolerabilityOther: Placebo pharmacokineticsDrug: F901318 pharmacokinetics
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 46
- Registration Number
- NCT02394483
- Locations
- 🇬🇧
Simbec Orion, Merthyr Tydfil, Wales, United Kingdom
F901318 Multiple Ascending Dose Study
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT02342574
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, UK, United Kingdom
F901318 Single Ascending Dose Study in Healthy Male Volunteers
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT02142153
- Locations
- 🇬🇧
Simbec Research, Merthyr Tydfil, Mid Glamorgan, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath